Did you get given information about your e-cadherin status?

ingersollnic

http://www.news-medical.net/news/20151009/Research...

The study also reaffirmed a previous finding that loss of the function of a molecule called e-cadherin is the hallmark of invasive lobular carcinoma, and it uncovered new mutations in genes that regulate estrogen receptor signaling in these cancers.

I have not been given any information on it and was wondering if other women had this information?

Bellis

I have not received any information about it but read about it in my pathology results. Mine is negative but it is not necessary true for all lobular cancers. Actually I have come accross som studies that say that loss of e-cadherin is a poor prognostic factor for ilc

http://onlinelibrary.wiley.com/doi/10.1111/his.12572/full

" E-cadherin-negative ILC had a poorer prognosis compared to E-cadherin positive ILC and to IDC regardless of E-cadherin status."

Anonymous

I've never heard of it and not sure I want to check my pathology report, now 4 years old, to find out.

MelissaDallas

It is the test they do to confirm lobular versus ductal cancer. My LCIS pathology report has information that it was confirmed via ecadherin testing..

wallycat

I'm also 8-1/2 years out and do not want to look at my old pathology report. I've been "odd" on every prognosticating area....oncotype, age, history, blah, blah....

momand2kids

Never heard of it--- and at over 7 years out, not poking that bear!!!!

jojo9999

Bellis, I am confused about the testing for CHD1. I had genetic testing done - on a blood sample, not the tumor - it looks for 17 gene mutations, one of which is CDH1. Mine came back negative. Are you saying that your tumor sample was testing for e-cadherin? and is that the same thing as CDH1?

ingersollnic

From what I have read, the loss of it is common amongst ILC and sometimes if they are unsure, yes they would use that fact to classify as ILC or IDC. I am reading the recent study on the comprehensive molecular portraits of ILC and it shows CDH1 and PTEN loss, AKT activation and mutations in TBX3 and FOXA1 and they have classified ILC into 3 subgroups.

E-cadherin loss is considered the hallmark lesion and showed in nearly all ILC samples, I just never saw it in my pathology reports

614

I am going to look at my pathology reports.  Thanks.

614

My pathology report states that there was no E-cadherin present in my tumor which confirmed the diagnosis of ILC.  

MelissaDallas

Bellis, it may not be true of ALL but it is true in 97%. That is why they use the test as the determiner for ductal v. Lobular.. As far as DNA testing of the tumor and the sub-types of ILC, this is very new research and not being done routinely as far as treatment considerations yet as I understand it

JohnSmith

This topic of new ILC subtypes is interesting. There's a few threads discussing it, including here.

1. The takeaway is that there is no standard test to define your ILC subtype. It will take years for that.
The good news is that a number of the ILC targets revealed from this large study are in clinical trial.
Recently, PI3K and AKT inhibitors entered clinical trials for several cancer types including breast cancer. ILC has on average the highest levels of Akt activation among all breast cancer subtypes (comparable to IDC basal-like), making selective inhibition of this pathway in ILC a particularly attractive strategy.
In other words, ILC women may benefit from clinical trials that use PI3K and/or AKT inhibitors.

2. Now, in terms of this Ecad study that Bellis posted.
This is such a puzzling study, since the hallmark of ILC is lack of Ecad.
I don't follow the world of pathology to understand how they define "moderate or strong continuous membrane staining for Ecad".
It sounds terribly subjective and perhaps even wrong (i.e. the 27 samples [23.3%] they define as Ecad+ might actually be misclassified and shouldn't even be considered Lobular).
Regardless, this is research that isn't clinically relevant. There is no standard test to determine the percentage of tumor cells that had "moderate or strong continuous membrane staining for Ecad".
In other words, this won't appear on your pathology report.
In fact, I just confirmed this with an ILC researcher. Ignore this Ecad study.

614

Thanks JohnSmith.